Breast Cancer Gene (BRCA) Mutations Treatment Market Report 2025

The breast cancer gene (BRCA) mutations treatment market size has grown strongly in recent years. It will grow from $4.67 billion in 2024 to $5.01 billion in 2025 at a compound annual growth rate (CAGR) of 7.4%. The growth during the historic period can be attributed to the expanding availability of genetic testing, increasing government and private investments in oncology research, rising demand for personalized medicine, growing adoption of preventive healthcare practices, and a higher number of at-risk populations undergoing screening.

The breast cancer gene (BRCA) mutations treatment market size is expected to see strong growth in the next few years. It will grow to $6.56 billion in 2029 at a compound annual growth rate (CAGR) of 7%. The growth during the forecast period can be attributed to the increasing incorporation of genetic testing in insurance coverage, growing demand for companion diagnostics, heightened focus on hereditary cancer screening programs, expanding clinical trials targeting BRCA-related cancers, and rising adoption of risk-reducing surgical procedures. Key trends expected in the forecast period include advancements in gene editing technologies, innovations in non-invasive diagnostic methods, integration of artificial intelligence and machine learning in genetic risk assessment, progress in liquid biopsy applications for BRCA-related cancers, and the development of personalized treatment algorithms.

The rising demand for targeted therapies is expected to drive the growth of the breast cancer gene (BRCA) mutation treatment market in the coming years. Targeted therapies are designed to specifically attack cancer cells by focusing on genetic mutations or proteins that drive cancer progression. Their increasing popularity stems from their ability to selectively target disease-causing cells while minimizing harm to healthy tissues, resulting in greater treatment effectiveness and fewer side effects than conventional therapies. Targeted therapies enable precision treatment of BRCA mutations by addressing the specific genetic alterations responsible for the disease, improving outcomes and reducing unnecessary adverse effects. For example, in July 2023, a report by the American Society of Gene & Cell Therapy (ASGCT), a US-based professional organization, noted that the number of gene therapies in Phase II increased from 247 at the end of Q1 2023 to 260 by the end of Q2 2023, marking a 5% rise. Thus, the growing demand for targeted therapies is propelling the expansion of the BRCA mutation treatment market.

Key players in the BRCA mutation treatment market are developing advanced therapies, such as adjuvant treatments, to enhance therapeutic success and patient outcomes. Adjuvant treatment refers to a supplementary therapy given after the primary treatment to eliminate residual cancer cells and reduce the risk of recurrence, thereby improving overall survival. For instance, in August 2022, AstraZeneca plc, a UK-based biotechnology company, and Merck & Co., Inc., a US-based pharmaceutical company, launched LYNPARZA (olaparib), which received European Commission approval for adults with germline BRCA-mutated, HER2-negative high-risk early breast cancer. LYNPARZA can be used alone or alongside endocrine therapy for patients previously treated with neoadjuvant or adjuvant chemotherapy. Approval was based on results from the phase 3 OlympiA trial, which showed a significant improvement in invasive disease-free survival and overall survival, substantially reducing the risk of breast cancer recurrence or death.

In October 2024, Owkin Inc., a US-based biotechnology company, partnered with AstraZeneca plc to accelerate and expand access to gBRCA pre-screening. The collaboration aims to develop an AI-driven gBRCA pre-screening tool that analyzes digitized pathology slides, speeding up and broadening access to BRCA mutation testing for breast cancer patients. AstraZeneca plc specializes in providing treatments for BRCA-mutated breast cancer.

Major players in the breast cancer gene (brca) mutations treatment market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Thermo Fisher Scientific Inc., AstraZeneca PLC, Novartis AG, GSK plc, Janssen Biotech Inc., Astellas Pharma Inc., Agilent Technologies Inc., Genentech Inc., Illumina Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., Invitae Corporation, Guardant Health Inc., Clovis Oncology Inc., Owkin Inc., Allarity Therapeutics Inc., VBL Therapeutics.

North America was the largest region in the breast cancer gene (BRCA) mutations treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in breast cancer gene (BRCA) mutations treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the breast cancer gene (BRCA) mutations treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

Breast cancer gene (BRCA) mutation treatment refers to therapies aimed at managing and reducing the risk of breast and ovarian cancers in individuals carrying harmful BRCA1 or BRCA2 mutations. The goal is to enable early detection of mutations and implement preventive strategies to improve patient outcomes.

The primary types of BRCA mutation treatments include targeted therapies, chemotherapy, hormonal therapy, and immunotherapy. Targeted therapies are designed to specifically interfere with molecules or pathways essential for cancer cell growth, allowing precise treatment while minimizing damage to healthy cells. These therapies are applied across various indications, including breast, ovarian, pancreatic, and prostate cancers. They are administered through multiple routes, such as oral, intravenous, and subcutaneous, and are utilized by a range of end users, including hospitals, clinics, and specialized cancer centers.

The breast cancer gene (BRCA) mutation treatment market research report is one of a series of new reports that provides breast cancer gene (BRCA) mutation treatment market statistics, including the breast cancer gene (BRCA) mutation treatment industry global market size, regional shares, competitors with the breast cancer gene (BRCA) mutation treatment market share, detailed breast cancer gene (BRCA) mutation treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the breast cancer gene (BRCA) mutation treatment industry. This breast cancer gene (BRCA) mutation treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The breast cancer gene (BRCA) mutations treatment market consists of revenues earned by entities by providing services such as genetic testing and counseling, targeted therapy administration, radiation therapy, surgical interventions (including mastectomy and oophorectomy), and post-treatment follow-up care. The market value includes the value of related goods sold by the service provider or included within the service offering. The breast cancer gene (BRCA) mutations treatment market also includes sales of genetic breast cancer gene (BRCA) testing kits, homologous recombination deficiency (HRD) assays, imaging tools, and emerging preventive immunotherapy vaccines. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.